Guardant Health
Genomic liquid biopsy platform detecting cancer-related genetic alterations from a simple blood sample.
What it does
Guardant Health is a precision oncology company that uses AI and liquid biopsy technology to detect, characterize, and monitor cancer through blood tests rather than tissue biopsies. Its products include Shield (a blood test for early colorectal cancer detection), Guardant360 (a comprehensive genomic profiling test for advanced cancer patients to identify targeted therapy options), and Guardant Reveal (a test for residual disease detection after treatment). AI is used throughout - analyzing the genomic alterations detected in circulating tumor DNA, distinguishing tumor-derived signal from background noise, and interpreting results in the context of approved targeted therapies. Guardant's tests are FDA-cleared or authorized and reimbursed by Medicare.
Why AI-NATIVE
Guardant Health is AI-native in its analytical layer - the detection of circulating tumor DNA, classification of genomic alterations, and clinical interpretation of results all depend on machine learning models trained on large genomic and clinical datasets.
Best for
Large hospital systems, cancer centers, and oncology practices use Guardant360 to guide treatment decisions for advanced cancer patients - AI-powered genomic profiling identifies actionable mutations that match patients to targeted therapies and clinical trials.
Limitations
Blood-based genomic testing may miss some alterations detectable in tissue — particularly in early-stage disease where circulating tumor DNA concentrations are low. Clinical context determines whether liquid biopsy is appropriate versus tissue biopsy.
While Medicare coverage exists for approved indications, commercial insurance reimbursement for liquid biopsy tests varies by payer and indication — out-of-pocket costs can be significant for some patients.
Guardant tests complement but do not replace standard cancer screening guidelines — Shield for colorectal cancer is an alternative to colonoscopy for appropriate patients, not an addition for all risk levels.
Alternatives by segment
| If you need… | Consider instead |
|---|---|
| Multi-cancer early detection | Grail |
| Tissue-based genomic profiling | Foundation Medicine |
| Oncology clinical decision support | Innovaccer |
Guardant360 CDx list price is approximately $5,000 per test. Shield colorectal cancer screening is reimbursed by Medicare at approximately $500. Institutional contracts with health systems may include volume pricing. Patient assistance programs available.
2026-03-31
